
- /
- Supported exchanges
- / US
- / BPMC.NASDAQ
Blueprint Medicines Corp (BPMC NASDAQ) stock market data APIs
Blueprint Medicines Corp Financial Data Overview
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Blueprint Medicines Corp data using free add-ons & libraries
Get Blueprint Medicines Corp Fundamental Data
Blueprint Medicines Corp Fundamental data includes:
- Net Revenue: 509 M
- EBITDA: -195 752 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -1.66
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Blueprint Medicines Corp News

Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Blueprint Medicines (NASDAQ:BPMC) First Quarter 2025 Results Key Financial Results Revenue: US$149.4m (up 56% from 1Q 2024). Net income: US$496.0k (down 99% from 1Q 2024). Profit margin: 0.3% (down ...


Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
Blueprint Medicines Corporation BPMC reported first-quarter 2025 adjusted loss of 74 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 42 cents. The adjusted figure exclu...

Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ...
AYVAKIT Revenue: $149.4 million in global net product revenues, with $129.4 million from the US and $20 million from ex-US markets. Revenue Growth: 61% year-over-year growth in AYVAKIT revenue. Revenu...

Q1 2025 Blueprint Medicines Corp Earnings Call
Participants Jenna Cohen; Vice President, Investor Relations & Global Business Communications; Blueprint Medicines Corp Kathryn Haviland; President, Chief Executive Officer, Director; Blueprint Medi...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.